文献速递膀胱癌与上尿路尿路上皮癌

原发肿瘤部位手术在转移性上尿路尿路上皮癌中的作用:系统综述与荟萃分析

The role of primary tumour site surgery in metastatic UTUC: a systematic review and meta-analysis.
PubMed 文献 · BJU Int · 2025-07-03

多数研究报告手术组在无进展生存、癌症特异性生存和总生存方面优于单纯系统治疗;系统治疗联合巩固手术的OS HR为0.66(95%CI 0.55-0.81),减瘤手术联合系统治疗的OS HR为0.73(95%CI 0.68-0.78)。结论认为手术可能改善生存,但证据主要来自回顾性研究且存在选择偏倚,需前瞻性研究确认并建立患者选择标准。

要点

  • 原发肿瘤手术可能与mUTUC患者更好的PFS、CSS和OS相关。
  • 系统治疗联合巩固手术的OS HR为0.66(95%CI 0.55-0.81)。
  • 减瘤手术联合系统治疗的OS HR为0.73(95%CI 0.68-0.78)。

核心结论

  • 与原发肿瘤非手术管理相比,手术可能改善mUTUC患者的生存结局。
  • 当前证据主要来自回顾性研究,存在潜在选择偏倚,需前瞻性研究确认。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed/Medline、Embase、Web of Science和Cochrane Library截至2025年1月的文献。
  • 干预为原发肿瘤手术,对照为非手术治疗(化疗、免疫治疗、放疗或最佳支持治疗)。

主要发现

  • 多数研究报告手术组相比单纯系统治疗(STx)在PFS、CSS和OS上有显著改善。
  • 系统治疗联合巩固手术与更优OS相关(HR 0.66,95%CI 0.55-0.81)。
  • 减瘤手术联合系统治疗与更优OS相关(HR 0.73,95%CI 0.68-0.78)。
  • 年轻患者和单一转移部位患者中观察到最有利的结局。

关键数值与推荐

  • 纳入标准:成人(≥18岁)mUTUC(cM+,排除cN+M0)。
  • 干预组:原发肿瘤手术;对照组:非手术治疗包括化疗、免疫治疗、放疗或最佳支持治疗。
  • 主要结局:手术/围手术期结局、PFS、CSS和OS。

临床怎么用

  • 对于年轻、单一转移部位的mUTUC患者,原发肿瘤手术可能作为改善生存的选择之一。
  • 系统治疗联合巩固手术或减瘤手术联合系统治疗均与OS改善相关,可个体化考虑。
  • 因证据来自回顾性研究,临床决策需结合患者选择偏倚风险并等待前瞻性研究验证。

局限性

  • 纳入研究均为回顾性设计,存在潜在选择偏倚。
  • 需前瞻性研究确认 findings 并建立可从手术获益的患者选择标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the impact of primary tumour surgery on survival outcomes in patients with metastatic upper urinary tract urothelial carcinoma (mUTUC) by conducting a systematic review and meta-analysis. METHODS: A systematic search was conducted using the PubMed/Medline, Embase, Web of Science, and Cochrane Library databases for studies published up to January 2025, using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Eligible studies included adult patients (≥18 years) diagnosed with mUTUC (cM+ excluding cN + M0). The intervention assessed was primary tumour surgery, compared to non-surgical management, including chemotherapy, immunotherapy, radiation therapy, or best supportive care. Key outcomes measured were surgical/peri-operative outcomes, progression-free survival (PFS), cancer-specific survival (CSS) and overall survival (OS). RESULTS: Ten eligible retrospective studies were identified. Most reported a significant improvement in survival outcomes (PFS, CSS and OS) for patients undergoing primary tumour surgery compared to systemic therapy (STx) alone. Surgery was notably associated with superior OS both for STx plus consolidative surgery (hazard ratio [HR] 0.66, 95% confidence interval [CI] 0.55-0.81) and cytoreductive surgery plus STx (HR 0.73, 95% CI 0.68-0.78). The most favourable outcomes were observed in younger patients and those with a single metastatic site. CONCLUSIONS: Surgery may improve survival outcomes in mUTUC compared to non-surgical options. However, the current evidence is mainly derived from retrospective studies with potential selection bias. Prospective studies are needed to confirm these findings and establish criteria for selecting patients who could benefit from surgical intervention.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Cella L, Moretto S, Contieri R, et al. The role of primary tumour site surgery in metastatic UTUC: a systematic review and meta-analysis. BJU Int. 2025. PMID: 40607943. doi:10.1111/bju.16836

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。